Company

Staten Biotechnology

Staten is leading the next step in dyslipidemia management. Dyslipidemia is an abnormal amount of lipids or fat in the blood, namely triglycerides, cholesterol, or fat phospholipids. In developed countries most dyslipidemias are hyperlipidemia, i.e. elevation of lipids in the blood, and can be caused by genetic factors, diet, and lifestyle. Reduction of these lipids in the blood is known to have a positive impact in vascular and heart diseases. Staten is developing a human monoclonal antibody with a unique approach towards neutralizing apoC3 – a key molecule in dyslipidemia management – which reduces triglyceride levels and increases removal of atherogenic lipoprotein remnant particles.

Staten Biotechnology

Transistorweg 5J (Building M)

6543 AT Nijmegen

The Netherlands

+31 35 760 65 00

info@statenbiotech.com

Website

More companies in this area

SPL Medical

SPL Medical is strongly committed to improve MRI imaging to enable a much more precise, effective and patient friendly diagnosis of cancer metastasis.

QM Diagnostics

QM Diagnostics is an internationally operating, independent and innovative diagnostic microbiological laboratory.

We are specialized in health monitoring of small laboratory animals used for biomedical research.

Cardiacbooster

Developing the next generation of percutaneous left ventricular assist devices.

ATRO Medical

ATRO Medical is working hard on the transition to the clinic and the first implantation of a Trammpolin™ meniscus prosthesis in the patient is expected in 2020.

Enzyre

Enzyre will enable personalized diagnostics by developing disposable biochips measuring, in one drop of blood, multiple parameters of specific interest to each patient group, with higher accuracy and at lower costs.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!